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ABSTRACT: Antimicrobial resistance (AMR) has been
identiﬁed as a major threat to public health worldwide. To
ensure appropriate use of existing antibiotics, rapid and
reliable tests of AMR are necessary. One of the most common
and clinically important forms of bacterial resistance is to β-
lactam antibiotics (e.g., penicillin). This resistance is often
caused by β-lactamases, which hydrolyze β-lactam drugs,
rendering them ineﬀective. Current methods for detecting
these enzymes require either time-consuming growth assays or
antibiotic mimics such as nitroceﬁn. Here, we report the
development of a surface-bound, clinically relevant β-lactam
drug that can be used to detect β-lactamases and that is
compatible with a range of high-sensitivity, low-cost, and label-free analytical techniques currently being developed for point-of-
care-diagnostics. Furthermore, we demonstrate the use of these functionalized surfaces to selectively detect β-lactamases in
complex biological media, such as urine.
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■ INTRODUCTION
Antimicrobials are vital for the treatment and prevention of
bacterial infections. However, infections that were once simple
to remedy are becoming increasingly resistant to treatment.1
Although the emergence of antimicrobial resistance (AMR) is
inevitable through evolution of bacteria via natural selection,
increased exposure as a result of the misuse and overuse of
antibiotics has accelerated the development of AMR
globally.2,3 Conventional methods used to identify antimicro-
bial susceptibility can take days to complete and often require
isolation and culturing of the pathogenic bacteria.4 In order to
preserve the eﬃcacy of antimicrobial agents, it is imperative
that the prescribing practice for antibiotics is improved by
allowing clinicians to perform rapid and reliable tests of
susceptibility. β-Lactam-based antimicrobials are one of the
most commonly used classes of antibiotic.5 As a defense
against these drugs, many bacteria are able to produce enzymes
that hydrolyze the drug’s pharmacophore (the β-lactam),
rendering the drug inactive. Resistance to these classes of
antibiotics is common, resulting in the restricted use of
previously eﬀective antibiotics, such as the earlier generations
of penicillins. By detecting the presence (or absence) of β-
lactamases, a susceptibility proﬁle to these drugs can be
deduced for a given infection and thus a suitable antibiotic can
be prescribed. There are a number of methods currently
available for the detection of β-lactamases, but these are
limited to solution-phase assays.6−11 A surface-based assay of
β-lactam resistance would be compatible with a range of high-
sensitivity, low-cost, and label-free analytical techniques
developed for point-of-care diagnostics.12−16
Herein, we report the development of a surface-bound
antibiotic able to respond to the presence of β-lactamases,
which is compatible with the wide range of emerging surface-
sensitive biosensing technologies. Hydrolysis of the surface-
bound β-lactams by β-lactamases indicates resistance to the
drug. Here, cephalexin (1) was identiﬁed as a suitable substrate
for immobilization. This ﬁrst-generation cephalosporin is used
widely for the treatment of bacterial infections.17 Furthermore,
the amine present in the drug’s structure provides an ideal
functional moiety for addition of a chemical tether (2), remote
from the pharmacophore. This allows the compound to be
anchored to a variety of surfaces, while minimizing the eﬀect
on the drug’s activity (Scheme 1).18
■ RESULTS AND DISCUSSION
A previous report has shown the preparation of a β-lactam-
modiﬁed gold surface using a tether with a cyclic disulﬁde.19
However, as many of the β-lactam antimicrobials feature a
sulfur group within the core structure of the molecule, the
orientation in which these molecules are bound to the surface
remains ambiguous.20 To ensure that the cephalexin molecules
used here are immobilized on the surfaces in the optimal
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orientation, a two-step process was employed. Initially, the
surface was modiﬁed with a self-assembled monolayer (SAM)
with thiol terminal groups. The antibiotic was subsequently
anchored to the thiolated surface via the maleimide tethered to
the amine of cephalexin (2) (Scheme 1).
Ideally, the surface should enable β-lactamases to access the
drug, hydrolyze the β-lactam, and then ultimately detach from
the surface. A previously reported co-crystal structure of a β-
lactamase bound to a β-lactam-based inhibitor was employed
in the design of compound 2, to ensure that the tether was of
suﬃcient length to distance the cephalexin from the surface
and allow enzyme access (S1.1).21 A polyethylene glycol
(PEG) chain was chosen as these molecules are well known to
inhibit physisorption of proteins onto surfaces, while providing
conformational ﬂexibility.22,23 The thiol SAM was formed on
an Au surface using 1,3-propanedithiol (Scheme 1). Control
reactions conﬁrmed that thiol addition was selective for the
maleimide over the β-lactam (S1.7).
Polarization modulation infrared reﬂection adsorption
spectroscopy (PM-IRRAS) allows direct chemical analysis of
SAMs24 and was employed here to conﬁrm hydrolysis of this
surface-bound antibiotic by β-lactamases. PM-IRRAS of a
cephalexin-PEG functionalized Au surface revealed a band at
around 1776 cm−1, consistent with the carbonyl of the β-
lactam, conﬁrming that the pharmacophore of the immobilized
antibiotic remained intact (Figure 1). With a surface of
cephalexin successfully prepared, the sample was immersed in a
solution of potassium phosphate buﬀer (KPi) spiked with β-
lactamases and incubated for 2 h to allow for the enzymes to
hydrolyze the surface-bound cephalexin. PM-IRRAS showed
the loss of the β-lactam carbonyl band, conﬁrming that
hydrolysis had occurred (Figure 1).
Control reactions demonstrated the stability of the surface-
bound drug in the absence of β-lactamases, verifying that
hydrolysis was a result of the enzyme-catalyzed reaction (S3.1
IR08). Whereas PM-IRRAS conﬁrmed that β-lactamases were
able to hydrolyze the immobilized cephalexin, IR absorption in
the amide I band region (1666 cm−1) indicated that protein
fouling of the surface was occurring.
Quartz crystal microbalance with dissipation (QCM-D)
monitoring was employed to further study the surface-bound
drug, enabling quantiﬁcation of the surface concentration of
proteins and other molecules [calculated using the Sauerbrey
equation (S3.2)]. For clarity, the frequency data are discussed
herein, with dissipation data included in the Supporting
Information (S3.3.). To explore the versatility of the surface-
bound antibiotic, we investigated two diﬀerent QCM-D
sensors coated with Au or SiO2. Cephalexin-PEG (2) was
immobilized on the Au-coated sensors via a thiol SAM formed
using 1,3-propanedithiol. The surface chemistry was adapted
for the SiO2 sensors using 3-mercaptopropyltriethoxysilane
(MPTES) to thiolate the surface. The surface concentration of
cephalexin-PEG (2) was found to be comparable on both the
Au- and SiO2-coated sensors (Figure 2). Both coatings were
calculated to have approximately 1.77 × 1014 molecules/cm2
(typical for a PEG monolayer)25,26 of cephalexin-PEG (2)
bound, demonstrating the generality of the surface chemistry.
The two surfaces (Au and SiO2) were studied further to
examine the interaction of β-lactamases with the surface-bound
antibiotics. We found that physisorbed β-lactamases could be
eﬀectively removed from both the Au and SiO2 surfaces
functionalized with cephalexin-PEG (2) by washing with a 2%
sodium dodecyl sulfate (SDS) solution (S3.3 QCM02).
Complementary experiments using a cephalexin analogue
with a short alkane tether showed increased biofouling,
conﬁrming the eﬀectiveness of the PEG linker in minimizing
Scheme 1. Design of the Surface-Bound Antibiotica
aSAM formation and attachment of cephalexin via a maleimide tether.
For Au surfaces, X = SH; for SiO2 surfaces, X = Si(OEt)3. Inset:
Structure of cephalexin (1) and cephalexin-R-maleimide (2), where R
= CH2OCH2C(O)NHCH2PEG4CH2NHC(O)(CH2)5.
Figure 1. Structure of cephalexin-PEG-maleimide (2). PM-IRRAS
spectra of the cephalexin-PEG surface before (red) and after (blue)
exposure to β-lactamases.
Figure 2. QCM-D experiment monitoring cephalexin-PEG (2)
binding to the thiolated surfaces of SiO2 and Au sensors. The
introduction of each solution is indicated by labeled arrows and
dashed lines.
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protein physisorption (S3.3 QCM02). We note that the
cephalexin-PEG monolayer was found to be stable following
exposure to 2% SDS (S3.1 IR08). Additional QCM-D analyses
(discussed below) were performed using both Au and SiO2
sensors to demonstrate the versatility of the surface-bound
antibiotic. For clarity, the Au data are discussed herein, with
data for the SiO2 surfaces included in the Supporting
Information (S3.3).
As the drug−enzyme complex is short-lived and there is no
signiﬁcant change in mass of the surface-bound drug after β-
lactam hydrolysis, a suitable probe is required to conﬁrm the
hydrolysis reaction when using QCM-D. A penicillin-binding
protein (PBP), the therapeutic target for β-lactam antibiotics,
was chosen as it binds covalently to the active site of the
protein. Because of the speciﬁcity of this protein, it allows for
detection of the orientation and state of the surface-bound β-
lactam (Figure 3a). Suitability of this probe was conﬁrmed
using a set of experiments in which three QCM-D sensors were
functionalized with cephalexin-PEG (2). One sensor was
exposed to PBP, the second was challenged with PBP which
had been pre-incubated with cephalexin (1) to block the
binding site, thus deactivating it, while the third was pre-
exposed to 1 M NaOH in order to chemically hydrolyze the β-
lactams. All sensors were then washed using a 2% SDS solution
in order to remove noncovalently bound PBPs.
A signiﬁcant shift in resonant frequency was observed only
when both the β-lactam was intact and the PBP was active
(Figure 3b). The average value of this frequency shift (−27
Hz) suggests that approximately 1 × 1013 PBPs/cm2 are
covalently bound to intact β-lactams on the surface. This
surface density is typical of a protein monolayer,27 suggesting
that around 7% of surface-immobilized cephalexin molecules
are bound to PBPs. This experiment conﬁrmed the suitability
of PBPs as a probe for the intact β-lactams. We note that when
the PBPs were covalently bound to the surface-bound
antibiotics, a large shift in frequency was observed following
the introduction of SDS (Figure 3b(1)). Because of the
covalent nature of the protein−drug bond, the surfactant
interacts with the PBPs, but is unable to remove the proteins
from the surface, causing a build-up of surfactant and a
concomitant increase in mass.
Having conﬁrmed that a PBP can function as a suitable
probe for β-lactam hydrolysis, additional measurements were
performed to further conﬁrm the activity of β-lactamases
against the cephalexin-PEG surface. As reported, a signiﬁcant
shift in frequency was observed following exposure of a
cephalexin-PEG surface to PBPs. In contrast, a signiﬁcantly
lower concentration of PBPs (5.7 × 1012 PBPs/cm2) was
observed after the cephalexin-PEG surface was ﬁrst challenged
with β-lactamases (Figure 4). It was also noted that the
frequency spike associated with the SDS wash was much
reduced for the sensor exposed to β-lactamases, indicating that
PBPs physisorb rather than covalently bind to the surface.
Control measurements using a β-lactamase inhibitor conﬁrmed
that the reduction in PBP binding was a result of β-lactam
hydrolysis, rather than nonspeciﬁc adsorption of the β-
lactamases blocking the surface (S3.3 QCM07/08). These
results combined with the PM-IRRAS data (Figure 1) conﬁrm
that β-lactamases are capable of hydrolyzing the surface-bound
antibiotics.
A stage often neglected in the development of novel
biosensors is the compatibility of the device, and thus the
sensor surface, with clinical samples. However, in order for
rapid testing to be a possibility, tests should ideally be
performed directly on clinical samples.28 To this end, we
Figure 3. (a) Use of PBP as a probe for QCM-D studies. (b) QCM-D
experiment of surface-bound cephalexin-PEG (2) on Au: (1) PBP
only; (2) PBP preincubated with cephalexin; (3) surface antibiotics
pre-treated with NaOH, a gap in the data indicates a skipped buﬀer
step. The introduction of each solution is shown by labeled arrows
and dashed lines. The number of PBPs bound after the ﬁnal wash is
shown for each sensor. Data reported as mean value ± standard
deviation.
Figure 4. QCM-D experiment of surface-bound cephalexin-PEG (2)
on Au: (1) PBPs only and (2) β-lactamases followed by PBPs. The
introduction of each solution is shown by labeled arrows and dashed
lines. The number of PBPs bound after the ﬁnal wash is shown for
each sensor. Data reported as mean value ± standard deviation.
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explored the robustness of the cephalexin-PEG surface for the
detection of β-lactamases in physiological samples, speciﬁcally
urine. Urine is analyzed routinely for diagnosis and
susceptibility testing of urinary tract infections but, as a
complex biological medium, it contains intact human cells,
proteins, and small molecules creating a challenge for in-matrix
detection. Gold samples were prepared with cephalexin-PEG
(2) for analysis by PM-IRRAS. These samples were then
exposed to urine spiked with β-lactamases or, as a control,
challenged with urine only. Both surfaces showed excellent
selectivity in response to β-lactamases, with reduction in the β-
lactam carbonyl band only being observed in the samples
exposed to urine spiked with β-lactamases (Figure 5a). The
preservation of the β-lactams in the control samples (i.e.,
without β-lactamases, Figure 5b) demonstrates the stability of
the surface-bound drug in urine over an extended time period.
We note that hydrolysis of the β-lactam was incomplete after
24 h. In contrast, experiments performed using β-lactamases in
buﬀer (Figure 1) showed loss of the β-lactam carbonyl band
after 2 h. It is likely that the high protein concentration of urine
resulted in increased surface biofouling, evidenced by a large
IR band with maximum absorbance at 1664 cm−1, which could
inhibit access to the surface-bound drug, thus inhibiting
complete hydrolysis.
Complementary experiments were performed using QCM-
D. The cephalexin-PEG monolayer, assembled on Au-coated
QCM-D sensors, was exposed either to urine spiked with β-
lactamases or to urine only. All sensors were washed in ﬂow
during the QCM-D measurement to ensure that each sample
was treated to the same washing procedures, allowing a
consistent baseline to be established (S3.3 QCM09/10).
Signiﬁcantly more binding of PBPs was observed on surfaces
that had not previously been exposed to β-lactamases (Figure
5c). Comparing the urine studies (Figure 5c) to previous
QCM-D experiments performed in buﬀer (Figure 4), it is clear
that the number of PBPs binding to the cephalexin-PEG
exposed to urine was reduced. This reduction in binding is
likely due to the large number of nontarget proteins in urine;
however, the surface still provides a robust and detectable
response despite these challenging conditions.
■ CONCLUSIONS
In conclusion, this work details the development of a surface-
bound antibiotic, able to detect the presence of β-lactamases in
urine. Studies using PM-IRRAS and QCM-D demonstrated
the successful hydrolysis of the surface-bound drugs by β-
lactamases and conﬁrmed the stability of the drug surface in
the absence of these enzymes, even in urine. Results obtained
from the antibiotic-functionalized Au and SiO2 surfaces were
comparable, demonstrating the versatility of this method. This
versatility could be exploited to allow integration of our novel
cephalexin-PEG (2) with a wide range of current and emerging
surface aﬃnity biosensor technologies that ultimately could
provide evidence-based diagnostics for the rational and
targeted prescription of antibiotics.
■ MATERIALS AND METHODS
Compound Synthesis. Details of the synthetic procedures,
compound characterization, and spectra are provided in the
Supporting Information (S1).
Materials. Planar gold surfaces were prepared for studies using
PM-IRRAS. Brieﬂy, samples were fabricated by electron beam
evaporation of 25 nm Ti/100 nm Au onto cleaned Si wafers
purchased from IDB Technologies. Gold (QSX 301)- and silicon
dioxide (QSX 303)-coated QCM-D sensors were purchased from
Biolin Scientiﬁc. Unless otherwise stated, solvents and reagents
purchased commercially were used without further puriﬁcation. 1,3-
Propanedithiol was purchased from Sigma-Aldrich and MPTES was
purchased from TCI Chemicals. DMSO was purchased from Fisher
Scientiﬁc.
Figure 5. PM-IRRAS and QCM-D studies in urine. (a) PM-IRRAS
test: before and after exposure to urine spiked with β-lactamases. (b)
PM-IRRAS control: before and after exposure to urine only. (c)
QCM-D experiment of surface-bound cephalexin-PEG (2) on Au: (1)
urine only and (2) urine spiked with β-lactamases. The introduction
of each solution is shown by labeled arrows and dashed lines. The
number of PBPs bound after the ﬁnal wash is shown for each sensor.
Data reported as mean value ± standard deviation.
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Instrumentation. PM-IRRAS spectra were acquired using a
Bruker Vertex 70 spectrometer coupled with a PMA50 polarization
modulation unit (Hinds Instruments, Oregon, USA). QCM-D spectra
were recorded on a QSense E4, QFM 401. The surface area exposed
to solution was equal to 0.95 cm2 as deﬁned by a Viton O-ring. The
temperature in the QCM-D chamber was controlled by a Peltier
device and was set to 37 °C (standard deviation 5 × 10−3 °C) for all
measurements.
Surface Functionalization. Gold wafers for PM-IRRAS were
cleaned by immersion in piranha solution (H2SO4/H2O2 70:30) for
10 min, followed by sonication in water and ethanol for 10 min each.
QCM-D sensors were cleaned by UV−ozone treatment (10 min),
followed by sonication in a 2% Hellmanex III solution (Hellma
Analytics, Müllheim, Germany) (10 min) and then sonication in
ultrapure water (2 × 10 min), followed by UV−ozone treatment (30
min) and immersion in EtOH (30 min). Cleaned samples were
functionalized according to the type of surface employed. Cleaned
gold samples were functionalized with 1,3-propanedithiol by 24 h
immersion in a 10 μM MeOH solution. However, cleaned silicon
dioxide samples were functionalized with MPTES by 24 h immersion
in 4% v/v MPTES/IPA solution. Following the formation of the thiol
SAM, samples were gently rinsed with ultrapure water and dried with
N2 gas. The samples were then immersed in the required cephalexin-
maleimide analogue solution (2 μM in 25% DMSO/H2O) for 24 h to
allow formation of the thiol−maleimide conjugate. Finally, the
samples were gently rinsed with 50% DMSO/H2O followed by
ultrapure water, then dried with N2 gas.
β-Lactamase Stock Solution. A blend of recombinant β-
lactamase proteins, expressed in Escherichia coli, was purchased from
Sigma-Aldrich (L7920) and used without further puriﬁcation. The
lyophilized powder was dissolved in 50 mM KPi (pH 7) and aliquoted
into 1 mL aliquots, each containing 40−70 IU β-lactamase I and 6−
10 IU β-lactamase II. The enzyme stock solutions were stored below 0
°C. For experiments testing the hydrolysis by β-lactamase, stock
enzyme solution was diluted ×6 in the required test solution.
Concentrations were maintained at this dilution throughout all
experiments.
Expression and Puriﬁcation of PBP. A truncated version of the
ftsI gene formed of residues W44-S588, encoding only the soluble
domain, was ampliﬁed from E. coli BW25113. The resulting construct
was inserted into the vector pBADnLIC2005,29 introducing an N-
terminal deca-histidine tag when expressed. The resulting vector was
transformed into E. coli MC1061 for expression. Cultures for protein
expression were grown in 1 L of Luria-Bertani broth at 37 °C on an
orbital shaker. Expression was induced by addition of 0.01% L-
arabinose during mid-log phase of growth. Cultures were further
incubated for 4 h and cells were harvested by centrifugation. Cell
pellets were resuspended in 50 mM KPi pH 7.8, 200 mM NaCl, 10
mM imidazole, 20% glycerol with 1 mM phenylmethylsulfonyl
ﬂuoride followed by sonication. The lysate was clariﬁed by
centrifugation before loading onto a HisTrap HF column (GE
Healthcare). To remove any pre-bound ligands, refolding puriﬁcation
was performed by initially washing with the protein unfolding buﬀer
[2 M guanidine HCl, 50 mM KPi (pH 7.8), 200 mM NaCl, 20%
glycerol, and 20 mM imidazole] and then performing a gradient wash
to the protein refolding buﬀer [50 mM KPi (pH 7.8), 200 mM NaCl,
20% glycerol, and 20 mM imidazole] before the elution of the protein
using the elution buﬀer [50 mM KPi (pH 7.8), 200 mM NaCl, 20%
glycerol, and 500 mM imidazole]. The eluted protein was buﬀer-
exchanged to the buﬀer 50 mM KPi (pH 7.8), 200 mM NaCl using a
HiTrap Desalting (GE Healthcare) column. Binding activity of the
puriﬁed E. coli PBP3 was conﬁrmed using a thermal shift assay; details
can be found in the Supporting Information (S2).
PBP Stock Solution. Protein concentration was determined using
the Beer−Lambert law from the absorbance at 280 nm with an
extinction coeﬃcient of 58 790 M−1 cm−1. For surface experiments
using PBP, solutions were prepared to 1 μM protein in 50 mM KPi
(pH 7).
Urine Samples. Urine samples were collected anonymously from
13 healthy adults that had not shown symptoms of infection or taking
antibiotics within 1 month prior to the sample collection. Participants
were recruited from within the University of York. Samples were ﬁlter-
sterilized using 0.22 μm syringe ﬁlters to remove any cells. The urine
samples were combined to form an “average” human urine, which was
aliquoted and stored in a −80 °C freezer. The pH of the resulting
urine was measured to be pH 6.7. Control experiments did not detect
any β-lactamases within the urine stock (S1.8).
PM-IRRAS Surface Studies. Following formation of the
functionalized surfaces, the gold wafers were immersed in the test
solution as described in the experimental procedures (Supporting
Information). Once the surface reactions were complete, the gold
wafers were cleaned according to the procedure detailed in the
Supporting Information and then loaded into the PM-IRRAS
spectrometer. The incident angle was set at 80° with a 4 cm−1
spectral resolution, while the PEM controller operated at 2000 cm−1.
Average measurement time was 15 min, collecting 1000 scans. Spectra
and experimental details of each sample analyzed are provided in the
Supporting Information (S3.1).
QCM-D Surface Studies. Following formation of the function-
alized surfaces, each sensor was then installed into the ﬂow modules
of the Q-Sense E4 system. Each chamber was then ﬁlled with Milli-Q
water at a ﬂow rate of 100 μL/min controlled by a four-channel
peristaltic pump. To achieve a stable baseline, the running buﬀer was
left to ﬂow through the modules at 20 μL/min for 60−80 min until
the drift in frequency was <±1 Hz over 10 min. For all experiments,
the temperature of the modules was kept at 37 °C (standard deviation
5 × 10−3 °C) and the ﬂow rate was kept constant at 20 μL/min.
Buﬀer was allowed to ﬂow over the sensor surface between sample
injections until a stable level was achieved, corresponding to a drift in
frequency <±1 Hz over 10 min. QCM-D spectra showing both the
frequency and dissipation shifts for each experiment, with noteworthy
shifts in frequency being indicated by shaded horizontal bars, are
provided in the Supporting Information (S3.3). Surface concen-
trations of proteins were calculated using the Sauerbrey equation
(S3.2). We accept that this method of analysis assumes a thin, rigid,
and uniform layer, and is therefore only an estimated value.
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